T2 Biosystems (NASDAQ:TTOO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research report sent to investors on Saturday morning. The firm issued a sell rating on the medical equipment provider’s stock.

T2 Biosystems Stock Performance

Shares of NASDAQ TTOO opened at $0.43 on Friday. The business has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $2.58. T2 Biosystems has a one year low of $0.31 and a one year high of $6.95.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC purchased a new position in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems as of its most recent filing with the SEC. Institutional investors own 23.18% of the company’s stock.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.